MRCT to humanize antibody to treat AD

MRC Technologyand BioArctic Neuroscience have signed an collaborative research agreement to humanise a mouse antibody under development with BioArctic for the treatment of Alzheimer’s disease. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary humanisation technology to generate the humanised clinical candidate.

Domantis wins award

Domantis, a spin-out company from the MRC, is the first to win the UK Innovation in Drug…

TYSABRI gains market approval

Biogen Idec and Elan Corporation yesterday announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for the reintroduction of TYSABRI® (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses.

MRCT and Chinese National Centre collaborate on malaria

MRCT's Drug Discovery Group has developed a drug screening assay for a potential Malaria drug target called PfSub-1, a subtilisin-like protease, and successfully identified a small number of ‘hit’ compounds from its own in house chemical library. The collaboration with NCDS will allow the target to be screened against a much larger compound library. Apart from synthetic chemicals, the NCDS library also contains a large collection of compounds isolated from natural products including traditional Chinese herbs.